A Global Expanded Access study for ZTALMY (ganaxolone) Oral Suspension CV

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 19 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Aug 2024 According to a Marinus Pharmaceuticals media release, the company is targeting submission of an Investigational New Drug application for a novel oral ganaxolone prodrug in the fourth quarter of 2025
14 Nov 2023 New trial record
07 Nov 2023 According to a Marinus Pharmaceuticals media release, the company has initiated this Marinus Access Program which will be managed by Durbin, a leader in the international distribution of specialized pharmaceuticals.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com